Analystreport

Royalty Pharma plc (NASDAQ: RPRX) had its price target raised by analysts at UBS Group AG to $51.00.

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations